Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin

Journal of Cutaneous Pathology

Volumn 23, Issue 4, 1996, Pages 335-343

  Talve, Lauri Arvo Ilmar ^a,b   Collan, Yrjö Urho Ilmari ^a   Ekfors, Tauno Olavi ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL NUCLEUS; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; MITOSIS INDEX; MORPHOMETRICS; PROGNOSIS; SKIN CANCER; THICKNESS;

EID: 0029783806     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1996.tb01307.x     Document Type: Article

References (45)

1. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970: 172: 902.
2. Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Research 1969: 29: 705.
3. Baak JP, vanDiest PJ, Benraadt T et al. The multi-center morphometric mammary carcinoma project (MMMCP) in The Netherlands: value of morphometrically assessed proliferation and differentation. J Cell Biochem (Suppl.) 1993: 17G: 220.
4. Lipponen PK, Collan Y, Eskelinen MJ, Pesonen E, Sotarauta M. Morphometry in human transitional cell bladder cancer. Nuclear area and standard deviation of nuclear area - relation to tumor grade (WHO) and prognosis. Eur Urol 1990: 17: 155.
5. Artacho-Perula E, Roldan-Villalobos R, Martinez-Cuevas JF, Lopez-Rubio F. Nuclear quantitative grading by discriminant analysis of renal cell carcinoma samples. A patient survival evaluation. J Pathol 1994: 173: 105.
6. Marth C, Weger A, Muller-Holzner E, Zeimet AG, Moncayo-Naveda H. The prognostic value of nuclear roundness and neopterin in ovarian cancer. Eur J Cancer 1993: 29A: 1863.
7. Binder M, Dolezal I, Wolff K, Pehamberger H. Stereologic estimation of volume-weighted mean nuclear volume as a predictor of prognosis in "thin" malignant melanoma. J Invest Dermatol 1992: 99: 180.
8. Sørensen FB. Stereological estimation of nuclear volume in benign melanocytic lesions and cutaneous malignant melanomas. Am J Dermatopathol 1989: 11: 517.
9. Sørensen FB, Kristensen IB, Grymer F, Jakobsen A. DNA level, tumor thickness, and stereological estimates of nuclear volume in stage I cutaneous malignant melanomas. Am J Dermatopathol 1991: 13: 11.
10. Tan GJKH, Baak JPA. Evaluation of prognostic factors in stage I cutaneous malignant melanoma. Analyt Quant Cytol 1984: 6: 147.
11. Baak JPA, Tan GJKH. The adjuvant prognostic value of nuclear morphometry in stage I malignant melanoma of the skin. Analyt Quant Cytol Histol 1986: 8: 241.
12. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with human nuclear antigen associated with cell proliferation. Int J Cancer 1983: 31: 13.
13. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation -associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984: 133: 1710.
14. Barnard NJ, Hall PA, Lemoine NR, Kedar N. Proliferate index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987: 152: 287.
15. Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994: 57: 822.
16. Yamanaka N, Harabuchi Y, Kataura A. The prognostic value of Ki-R7 antigen in non-Hodgkin lymphoma of Waldeyer ring and the nasal cavity. Cancer 1992: 70: 2342.
17. Yamada Y, Murata K, Kamihira S et al. Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia. Cancer 1991: 67: 2605.
18. Smolle J, Hofmann-Wellenhof R, Kofler R, Soyer HP, Kerl H. Tumor cell proliferation and motility estimates are prognostic factors in malignant melanoma. Anal Cell Pathol 1993: 5: 113.
19. Blessing K, Kernohan NM, Park KG. Subungual malignant melanoma: clinicopathological features of 100 cases. Histopathology 1991: 19: 425.
20. Ohnishi K, Ishikawa H. Flow cytometric DNA analysis of primary cutaneous malignant melanoma. Acta Derm Venereol 1991: 71: 525.
21. Bartkowiak D, Schumann J, Otto FJ, Lippold A, Drepper H. DNA flow cytometry in the prognosis of primary malignant melanoma. Oncology 1991: 48: 39.
22. Korabiowska M, Brinck U, Hoenig JF, Bartkowski SB, Mirecka J, Schauer A. An application of MIB antibody to the retrospective study of melanomas of oral mucosa and facial skin. J Cancer Res Clin Oncol 1994: 120: 365.
23. Soyer HP. KI 07 immunostaining in melanocytic skin tumors. Correlation with histologic parameters. J Cutan Pathol 1991: 18: 264.
24. Nieminen S, Yli-Jama T, Hietanen T, Ekfors T, Nordman E. The increasing incidence and prognosis of skin melanoma in South Western Finland. Duodecim 1987: 103: 1134.
25. Kronqvist P, Collan Y, Kuopio T, Kujari H. Nuclear morphometry in breast cancer: The influence of sampling rules and freezing of samples. Mod Patho 1995: 8: 187.
26. Smolle J, Soyer HP, Juettner FM, Hoedl S, Kerl H. Nuclear parameters in the superficial and deep portion of melanocytic lesions. Path Res Pract 1988:183:266.
27. Smolle J, Hofmann-Wellenhof R, Soyer HP, Stettner H, Kerl H. Nuclear size and shape parameters correlate with proliferate activity in cutaneous melanocytic tumors. J Invest Dermatol 1989: 93: 178.
28. Klemi PJ, Takahashi S, Joensuu H, Kiilholma P, Narimatsu E, Mori M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994: 13: 228.
29. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993: 53: 365.
30. Stenmark-Askmalm M, Stal O, Sullivan S et al. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 1994: 30A(2): 175.
31. Ulbright TM, Orazi A, de Riese W et al. The correlation of p53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis. Mod Pathol 1994: 7: 64.
32. Castresana JS, Rubio MP, Vazquez JJ et al. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 1993: 55: 562.
33. Florenes VA, Ovjord T, Holm R et al. Tp53 allele loss, mutations and expression in malignant melanoma. Br J Cancer 1994: 69: 253.
34. Montano X, Shamsher M, Whitehead P, Dawson K, Newton J. Analysis of p53 in human cutaneous melanoma cell lines. Oncogene 1994: 9: 1455.
35. Volkenandt M, Schlegel U, Nanus DM, Albino AP. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 1991: 4: 35.
36. Kamb A, Gruis NA, Weaver-Feldhaus J et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994: 264: 436.
37. Hussussian CJ, Struewing JP, Goldstein AM et al. Germ-line p16 mutations in familial melanoma. Nat Genet 1994: 8: 15.
38. Kamb A, Shattuck-Eidens D, Eeles R et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994: 8: 23.
39. Ranade K, Hussussian CJ, Sikorski RS et al. Mutations associated with familial melanoma impair p16(INK4) function. Nat Genet 1995:10:114.
40. Kaudewitz P, Braun-Falco O, Ernst M, Landthaler M, Stolz W, Gerdes J. Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading. Am J Pathol 1989: 134: 1063.
41. Moretti S, Massobrio R, Brogelli L, Novelli M, Giannotti B, Bernengo MG. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. J Invest Dermatol 1990: 95: 320.
42. Ostmeier H, Suter L. The Ki-67 antigen in primary human melanomas - its relationship to mitotic rate and tumor thickness and its stability. Arch Dennatol Res 1989:281:173.
43. Rieger E, Hofmann-VVellenhof R, Sover HP et al. Comparision of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. J Cutan Pathol 1993: 20: 229.
44. Soyer HP, Smolle J, Smolle-Juettner FM, Kerl H. Proliferation antigens in cutaneous melanocytic tumors - an immunohistochemical study comparing the transferrin receptor and the Ki-67 antigen. Dermatologica 1989:179: 3.
45. Steinbeck RG, Heselmayer KM, Gerlach B, Björnhagen V, Auer GU. Diagnostic impact of nuclear DNA content and proliferative activity in benign and malignant melanocytic lesions. In: Björnhagen V. DNA content, morphometry and proliferation in melanocytic lesions. Karolinska Institute and Hospital, Stockholm, Sweden, 1994, 109-119, Thesis.